Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatments
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000023736
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1) Previous treatment with S-1 2) With active diseases (interstitial pneumonia, fibroid lung, intestinal obstruction, uncontrollable diabetes millutus or hypertentsion, history of myocardial infarction within 6 months, or unstable angina pectoris, liver cirrhosis, renal failure) 3) Simultaneous or metachronous cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer 4) History of severe allergic reactions to pyrimidine fluoride drug 5) Active infection 6) With severe diarrhea 7) With symptomatic metastasis to nerve 8) Psychosis 9) Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 10) Pregnant or lactating women, women of childbearing potential or women who like to have children in future 11) Participant to other clinical trials 12) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method